Viewing data from:

FLUVASTATIN SODIUM

ANDA

FLUVASTATIN SODIUM | A078407 | TEVA PHARMACEUTICALS USA

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Fluvastatin Sodium (2023)

Total Spending

$4.4M

Total Claims

19,892

Beneficiaries

6,093

Avg Cost/Unit

$2.95

Spending Trend

$2.8M(2019)→$3.4M(2020)→$3.8M(2021)→$4.4M(2022)→$4.4M(2023)

YoY Change:-6.6%

5yr CAGR:-2.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain6 active DMFs5 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

BIOCON LTDFLUVASTATIN SODIUM AMORPHOUS

DMF 184932005

BIOCON LTDFLUVASTATIN SODIUM

DMF 187622005

FIS FABBRICA ITALIANA SINTETICI SPAFLUVASTATIN SODIUM HYDRATE USP

DMF 189112005

TAPI NL BVFLUVASTATIN SODIUM

DMF 192962006

PHARMATHEN INDUSTRIAL SAFLUVASTATIN SODIUM AMORPHOUS

DMF 240912010

BIOCON LTDFLUVASTATIN SODIUM

DMF 367352022

CADILA HEALTHCARE LTDInactiveFLUVASTATIN SODIUM

DMF 178792004

USV LTDInactiveFLUVASTATIN SODIUM USP

DMF 205282007

LUPIN LTDInactiveFLUVASTATIN SODIUM (MICRONIZED) USP

DMF 215092008

AUROBINDO PHARMA LTDInactiveFLUVASTATIN SODIUM USP (NON-STERILE DRUG SUBSTANCE)

DMF 236572010

ZHEJIANG HISUN PHARMACEUTICAL CO LTDInactiveFLUVASTATIN SODIUM USP

DMF 259922012

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 20MG BASE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jun 12, 2012

No patent or exclusivity listings for this strength.

#002 — EQ 40MG BASE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jun 12, 2012